Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:BCDA NASDAQ:BIVI NASDAQ:EPIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsBCDABioCardia$2.11+1.0%$2.07$1.63▼$3.26$12.12M0.8550,390 shs37,032 shsBIVIBioVie$1.79-0.6%$4.67$1.42▼$75.00$13.56M0.66275,561 shs338,670 shsEPIXESSA Pharma$0.24+1.3%$1.48$0.22▼$7.88$11.21M1.617.37 million shs2.57 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%-95.37%BCDABioCardia+0.96%+6.57%+17.88%-6.22%-12.45%BIVIBioVie-0.56%+13.29%+7.19%-83.87%-92.95%EPIXESSA Pharma+1.31%+0.50%-87.43%-85.80%-95.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsBCDABioCardia$2.11+1.0%$2.07$1.63▼$3.26$12.12M0.8550,390 shs37,032 shsBIVIBioVie$1.79-0.6%$4.67$1.42▼$75.00$13.56M0.66275,561 shs338,670 shsEPIXESSA Pharma$0.24+1.3%$1.48$0.22▼$7.88$11.21M1.617.37 million shs2.57 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%-95.37%BCDABioCardia+0.96%+6.57%+17.88%-6.22%-12.45%BIVIBioVie-0.56%+13.29%+7.19%-83.87%-92.95%EPIXESSA Pharma+1.31%+0.50%-87.43%-85.80%-95.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.00Hold$3.621,895.87% UpsideBCDABioCardia 3.50Strong Buy$25.001,084.83% UpsideBIVIBioVie 4.00Strong BuyN/AN/AEPIXESSA Pharma 2.00Hold$2.00733.33% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04BCDABioCardia$60K203.97N/AN/A$0.18 per share11.72BIVIBioVieN/AN/AN/AN/A$9.93 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%N/ABCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/11/2025 (Estimated)BIVIBioVie-$17.54M-$79.10N/A∞N/AN/A-89.02%-75.32%9/29/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/ALatest AFMD, BCDA, BIVI, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025EPIXESSA Pharma-$0.17-$0.09+$0.08-$0.09N/AN/A8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69704.17%N/AN/A N/ALatest AFMD, BCDA, BIVI, and EPIX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93BCDABioCardiaN/A0.330.33BIVIBioVieN/A9.109.10EPIXESSA PharmaN/A69.0669.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%BCDABioCardia20.57%BIVIBioVie4.59%EPIXESSA Pharma75.12%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%BCDABioCardia20.00%BIVIBioVie2.39%EPIXESSA Pharma15.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableBCDABioCardia405.80 million4.64 millionOptionableBIVIBioVie107.53 million7.35 millionNo DataEPIXESSA Pharma5047.31 million39.98 millionOptionableAFMD, BCDA, BIVI, and EPIX HeadlinesRecent News About These CompaniesEssa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash DistributionAugust 25, 2025 | prnewswire.comEssa Pharma trading halted, news pendingAugust 25, 2025 | msn.comDLD Asset Management LP Makes New Investment in ESSA Pharma Inc. $EPIXAugust 22, 2025 | marketbeat.comESSA Pharma Inc. (NASDAQ:EPIX) Declares $1.69 -- DividendAugust 20, 2025 | marketbeat.comAldebaran Capital LLC Has $899,000 Holdings in ESSA Pharma Inc. (NASDAQ:EPIX)August 18, 2025 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPSAugust 16, 2025 | marketbeat.comESSA Pharma Announces $80M Capital DistributionAugust 14, 2025 | msn.comEssa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash DistributionAugust 14, 2025 | prnewswire.comESSA Pharma Inc. (NASDAQ:EPIX) Shares Sold by Altium Capital Management LLCAugust 14, 2025 | marketbeat.comESSA Pharma: Fiscal Q3 Earnings SnapshotAugust 13, 2025 | stamfordadvocate.comSEssa Pharma Inc. Announces US$80 Million Cash Distribution to ShareholdersAugust 6, 2025 | prnewswire.comESSA Pharma Announces Tax Implications of Cash DistributionAugust 1, 2025 | msn.comESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to ShareholdersJuly 23, 2025 | prnewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ESSA Pharma Inc. (NASDAQ: EPIX)July 14, 2025 | globenewswire.comEPIX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of ESSA Pharma Inc. is Fair to ShareholdersJuly 14, 2025 | businesswire.comESSA Pharma to be Acquired by XenoTherapeuticsJuly 14, 2025 | tipranks.comESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionJuly 14, 2025 | prnewswire.comEPIX | Essa Pharma Inc. Annual Income Statement - MarketWatchJuly 3, 2025 | marketwatch.comESSA Pharma Inc. Explores Strategic Alternatives After Clinical Trial TerminationMay 9, 2025 | tipranks.comESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comInvestor pressures struggling Essa to liquidate, give cash to shareholdersApril 16, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAFMD, BCDA, BIVI, and EPIX Company DescriptionsAffimed NASDAQ:AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.BioCardia NASDAQ:BCDA$2.11 +0.02 (+0.96%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.12 +0.01 (+0.47%) As of 09/9/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BioVie NASDAQ:BIVI$1.79 -0.01 (-0.56%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.56%) As of 09/9/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.ESSA Pharma NASDAQ:EPIX$0.24 +0.00 (+1.31%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$0.24 0.00 (-1.25%) As of 09/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
